55-70kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90. 2. Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. The best characterized activity of CD137 is its costimulatory activity for activated T cells.
Immobilized 4-1BB Ligand/TNFSF9 Fc Chimera , Cynomolgus at 2.0μg/mL (100μL/well) can bind Biotinylated 4-1BB/TNFRSF9 Fc&Avi Tag, Cynomolgus (Cat. No. UA010955) with EC50 of 8.45-11.22ng/mL.